Advertiser / Brand · vs · B2C Consumer App / Platform
Haleon vs Hims & Hers
Structured technology and market comparison · 2026
Direct Feature Comparison
Haleon · vs · Hims & HersPublic consumer healthcare brand owner focused on everyday health.
Consumer telehealth platform with subscription-based treatment and fulfilment.
Comparison Analysis
What is the main difference between Haleon and Hims & Hers?
When comparing Haleon and Hims & Hers, both platforms operate within the Advertiser / Brand and B2C Consumer App / Platform ecosystem. Haleon is positioned as Public consumer healthcare brand owner focused on everyday health, whereas Hims & Hers focuses on Consumer telehealth platform with subscription-based treatment and fulfilment. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Haleon and Hims & Hers?
When evaluating Haleon and Hims & Hers, enterprise buyers also consider other platforms in Advertiser / Brand and B2C Consumer App / Platform. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
Market Signals
Recent Market Signals & Activity: Haleon vs Hims & Hers
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Haleon
Recent Signals
No recent market signals documented for Haleon in the current tracking window.
Hims & Hers
Recent Signals
- ·PR Newswire: Technology NewsPrivacy
Hims & Hers Securities Fraud Class Action Filed
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company failed to disclose that it shared sensitive health information with third-party advertising platforms, including Snap and Meta (Facebook), and misled consumers about its billing practices, including premature prescription charges. The FTC filed a related lawsuit on July 29, 2026, prompting a 14.73% stock decline to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
- FTC sued Hims & Hers for sharing sensitive health data with advertising platforms and deceptive billing practices.
- Hims & Hers stock dropped $4.32 (14.73%) to $25.00 on July 29, 2026.
- Class action lawsuit filed; lead plaintiff deadline is November 2, 2026.
- ·Modern RetailProduct Design / D2C Pharmaceutical Convergence
Hims & Hers' Prescription Gummy Drives High Adherence
Hims & Hers launched a prescription Biotin + Minoxidil gummy for hair growth in June 2025. One year after launch the company surveyed 300 customers and reported an 88% daily adherence rate; 79% cited the green apple flavor as a reason for continued use and about two-thirds said the frosted glass jar packaging improved their experience. The article describes manufacturing and formulation challenges in creating a prescription-grade gummy and notes Hims & Hers' broader strategy of using design to de-stigmatize prescription products. The company reported $608.1 million in Q1 revenue in its May earnings report and gave full-year guidance of $2.8 billion to $3 billion.
- Hims & Hers launched the Biotin + Minoxidil Gummy (prescription) in June 2025.
- Hims & Hers surveyed 300 customers and reported an 88% daily adherence rate for the gummy.
- 79% of surveyed customers said the green apple flavor was a key reason they kept taking the gummy; nearly two-thirds said the frosted glass jar packaging made the experience more positive.
- ·techcrunchPrivacy
FTC sues Hims & Hers over sharing health data
The U.S. Federal Trade Commission has sued telehealth and consumer healthcare company Hims & Hers, alleging the company shared customers’ sensitive medical and healthcare information with advertisers and major tech firms including Meta and Snap, and misled consumers about its privacy practices. The FTC's complaint, filed in a California federal court, says Hims & Hers placed pixel-sized trackers from Meta, Snap, Microsoft, Pinterest, Reddit and X that captured and shared users’ health information. The complaint also accuses the company of deceptive billing practices and creating barriers to cancellation. Hims & Hers responded that its privacy policy enables users to choose how their data is used and said it will defend against the allegations. The action continues a pattern of FTC enforcement against healthcare-related companies over third-party web trackers.
- The Federal Trade Commission filed a lawsuit accusing Hims & Hers of sharing customers’ medical and healthcare information with advertisers and tech companies, including Meta and Snap.
- The FTC alleged Hims & Hers placed pixel-sized trackers provided by Meta, Snap, Microsoft, Pinterest, Reddit, and X that captured and shared users’ health information.
- The FTC also accused Hims & Hers of deceptive billing and designing policies that made it difficult for customers to cancel, in violation of federal consumer protection laws.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Haleon and Hims & Hers share across the market ecosystem.